Lansoprazole detailed information

Lansoprazole detailed information

File:Lansoprazole.svg
File:Lansoprazole 3D.png
Clinical data
[[Regulation of therapeutic goods |Template:Engvar data]]	US FDA: Lansoprazole
Pregnancy category	AU: B3 US: B (No risk in non-human studies)
Routes of administration	Oral, IV
ATC code	A02BC03 (WHO)
Legal status
Legal status	In general: ℞ (Prescription only)
Pharmacokinetic data
Bioavailability	80% or more
Protein binding	97%
Metabolism	Hepatic (CYP3A4- and CYP2C19-mediated)
Elimination half-life	1–1.5 hours
Excretion	Renal and fecal
Identifiers
IUPAC name 2-[(3-methyl-4-(2,2,2-trifluoroethoxy) pyridin-2-yl) methylsulfinyl] -1H-benzoimidazole
CAS Number	103577-45-3
PubChem CID	3883
DrugBank	APRD00077
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C16H14F3N3O2S
Molar mass	369.363 g/mol
3D model (JSmol)	Interactive image
SMILES O=S(Cc1nccc(OCC(F)(F)F)c1C)c1nc2ccccc2[nH]1

Lansoprazole (lan-SOE-pra-zole, INN) is a proton pump inhibitor which prevents the stomach from producing acid. It is manufactured by a number of companies worldwide under several trade names. It was first approved by the FDA in 1995 [1].

Pharmacology

Lansoprazole is a proton pump inhibitor (PPI) in the same pharmacologic class as omeprazole. Lansoprazole has been marketed for many years and is one of several PPI's available.

Lansoprazole's plasma elimination half-life is not proportional to the duration of the drug's effects (i.e. gastric acid suppression). The mean plasma elimination half-life is 1.5 hours, and the effects of the drug last for over 24 hours after it has been used for 1 day or more.

Indications

Lansoprazole is indicated for:

• Treatment of ulcers of the stomach and duodenum, and NSAID-induced ulcers
• Treatment of gastroesophageal reflux disease (GERD) (also known as acid reflux disease)
• Treatment of Zollinger-Ellison Syndrome
• Adjunctive treatment of Helicobacter pylori infection, alongside antibiotics

Drug Interactions

• PPI’s reduce absorption of antifungals (itraconazole and ketoconazole) and possibly increase Digoxin in plasma
• Increases plasma concentrations of Cilostazol (risk of toxicity)
• Absorption of lansoprazole possibly reduced by:
  • sucralfate
  • ampicillin
  • bisacodyl
  • delavirdine
  • fluvoxamine
  • iron salts
  • theophylline
  • voriconazole
  • aminophylline and theophylline
  • astemizole

Side effects

• Infrequent: dry mouth, insomnia, drowsiness, blurred vision, rash, pruritus
• Rarely and very rarely: taste disturbance, liver dysfunction, peripheral oedema, hypersensitivity reactions (including bronchospasm, urinary, angioedema, anaphylaxis), photosensitivity, fever, sweating, depression, interstitial nephritis, blood disorders (including leukopenia, leukocytosis, pancytopenia, thrombocytopenia), arthralgia, myalgia, skin reactions (including Stevens-Johnson syndrome, toxic epidermal necrolysis, bullous eruption)
• Severe: Gastro-intestinal disturbances (such as nausea 1.3%, abdominal pain 2.1%, diarrhea 3.8%

Brand names

File:Prevacid30mg.png

Prevacid 30 mg

The drug is sold under several brand names, including: [2]

• Aprazol (Turkey)
• Duogast (Syria)
• Lanpro (India)
• Lansox (Italy)
• Lanton (Israel)
• Lanzor (France)
• Laprazol (Greece)
• Limpidex (Italy)
• Ogast and OgastORO (France)
• Prevacid (U.S. and Canada) Prevacid is a product of TAP Pharmaceutical Products.
• Prosogan and Prosogan FD (Indonesia)
• Refluxon (Hungary)
• SOLOX (New Zealand)
• Takepron (Japan)
• Zoton (Italy, Ireland, Australia, UK)

Lansoprazole is also available as a generic drug in the UK, Belgium, France, Colombia, Italy and Mexico.

External links

• Prevacid (manufacturer's website)
• Prevacid Pediatrics (manufacturer's website)
• Prevpac (manufacturer's website)